Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Treatment of invasive candidiasis in the era of Candida resistance
Publication

Publications

Treatment of invasive candidiasis in the era of Candida resistance

Title
Treatment of invasive candidiasis in the era of Candida resistance
Type
Another Publication in an International Scientific Journal
Year
2023
Authors
Paiva, J-A
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Pereira, JM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
The Journal is awaiting validation by the Administrative Services.
Vol. 29
Pages: 457-462
ISSN: 1070-5295
Indexing
Publicação em ISI Web of Knowledge ISI Web of Knowledge - 0 Citations
Publicação em Scopus Scopus - 0 Citations
Other information
Authenticus ID: P-00Z-0ZM
Resumo (PT):
Abstract (EN): Purpose of reviewThe increasing incidence of drug-resistant Candida brings a new challenge to the treatment of invasive candidiasis. Although cross-resistance among azoles and echinocandins was generally uncommon, reports of multidrug-resistant (MDR) Candida markedly increased in the last decade. The purpose of this review is to understand mechanisms and risk factors for resistance and how to tackle antifungal resistance.Recent findingsThe paper describes the action of the three main classes of antifungals - azoles, echinocandins and polyenes - and Candida's mechanisms of resistance. The current evolution from cross-resistance to multiresistance among Candida explains the modern glossary - multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) - imported from bacteria. MDR Candida most commonly involves acquired resistance in species with intrinsic resistance, therefore it mostly involves C. glabrata, C. parapsilosis, C. krusei, C guilliermondii or C. auris, which is intrinsically multidrug resistant. Finally, strategies to tackle antifungal resistance became clearer, ideally implemented through antifungal stewardship.SummaryAvoiding antifungal's overuse and selecting the best drug, dose and duration, when they are needed, is fundamental. Knowledge of risk factors for resistance, microbiological diagnosis to the species, use of susceptibility test supported by antifungal stewardship programs help attaining effective therapy and sustaining the effectiveness of the current antifungal armamentarium.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 6
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

We May Be Using ICU Inefficiently for Patients With Severe Pneumonia: A Plea for a Different Intensivist's Role (2015)
Another Publication in an International Scientific Journal
Paiva, J-A; Pereira, JM
Treatment of the afebrile patient after catheter withdrawal: drugs and duration (2002)
Another Publication in an International Scientific Journal
Paiva, J-A; Pereira, JM
Severe sepsis in community-acquired pneumonia - Early recognition and treatment (2012)
Another Publication in an International Scientific Journal
Pereira, JM; Paiva, J-A; Rello, J
New antifungal antibiotics (2013)
Another Publication in an International Scientific Journal
Paiva, J-A; Pereira, JM
Fluoroquinolones: Another Line in the Long List of Their Collateral Damage Record (2015)
Another Publication in an International Scientific Journal
Paiva, J-A; Pereira, JM

See all (20)

Of the same journal

Infections in the critically ill patient: new challenges of an old problem (2023)
Another Publication in an International Scientific Journal
Paiva, J-A
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-19 at 12:47:50 | Privacy Policy | Personal Data Protection Policy | Whistleblowing